We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
Read MoreHide Full Article
Integer Holdings Corporation (ITGR - Free Report) recently completed the sale of its core Advanced Surgical and Orthopedics (“AS&O”) segment to MedPlast, LLC for $600 million. Following the announcement, the company’s share price rose 2.7% to close at $65.80.
Notably in the past six months, shares of Integer Holdings have rallied 46.8% against the industry’s decline of 7.6%.
The stock currently carries a Zacks Rank #2 (Buy).
Rationale Behind the Deal
The divestiture will help Integer Holdings reduce debt by approximately $500 million. With the paying down of debt, management expects Integer Holdings to be a $1.2 billion worth company.
The company is therefore expected to see higher margins, increased net earnings and greater returns on invested capital.
Furthermore, the increased financial flexibility will enable Integer Holdings to focus on its Cardio & Vascular and Cardiac & Neuromodulation product lines.
Focus on Cardiac Business
Integer Holdings’ cardiac business, comprising Cardio & Vascular and Cardiac/Neuromodulation units, has been a significant growth driver.
Notably, in the last reported quarter, the Cardio & Vascular product line saw strong year-over-year sales growth of 15.8% on robust demand for products and contract manufacturing components.
The Cardiac & Neuromodulation product line witnessed growth of 4.9% and remains a key driver of long-term growth.
Per management, the company is investing resources in these product lines to ensure innovation.
Market Prospects
Integer Holdings will be exposed to a highly profitable cardiovascular market space.
Per Research and Markets, the global market for cardiovascular devices market is expected to reach $59.1 billion by 2022 at a CAGR of 6.9%.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Genomic Health , Stryker Corporation (SYK - Free Report) and Masimo Corporation (MASI - Free Report) .
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Masimo has an expected long-term earnings growth rate of 14.6%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
Integer Holdings Corporation (ITGR - Free Report) recently completed the sale of its core Advanced Surgical and Orthopedics (“AS&O”) segment to MedPlast, LLC for $600 million. Following the announcement, the company’s share price rose 2.7% to close at $65.80.
Notably in the past six months, shares of Integer Holdings have rallied 46.8% against the industry’s decline of 7.6%.
The stock currently carries a Zacks Rank #2 (Buy).
Rationale Behind the Deal
The divestiture will help Integer Holdings reduce debt by approximately $500 million. With the paying down of debt, management expects Integer Holdings to be a $1.2 billion worth company.
The company is therefore expected to see higher margins, increased net earnings and greater returns on invested capital.
Furthermore, the increased financial flexibility will enable Integer Holdings to focus on its Cardio & Vascular and Cardiac & Neuromodulation product lines.
Focus on Cardiac Business
Integer Holdings’ cardiac business, comprising Cardio & Vascular and Cardiac/Neuromodulation units, has been a significant growth driver.
Notably, in the last reported quarter, the Cardio & Vascular product line saw strong year-over-year sales growth of 15.8% on robust demand for products and contract manufacturing components.
The Cardiac & Neuromodulation product line witnessed growth of 4.9% and remains a key driver of long-term growth.
Per management, the company is investing resources in these product lines to ensure innovation.
Market Prospects
Integer Holdings will be exposed to a highly profitable cardiovascular market space.
Per Research and Markets, the global market for cardiovascular devices market is expected to reach $59.1 billion by 2022 at a CAGR of 6.9%.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Genomic Health , Stryker Corporation (SYK - Free Report) and Masimo Corporation (MASI - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.
Masimo has an expected long-term earnings growth rate of 14.6%. The stock carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>